Abbott Launches New Psoriasisanswers.com Web site

AbbottAugust marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what's happening to them can be a challenge. Abbott has launched Psoriasisanswers.com, a new educational Web site created to clear up the myths and provide facts and useful tools for people living with psoriasis.

Psoriasis is a chronic, immune disease that causes red, itchy, flaky and sometimes painful patches of skin anywhere on the body. While the exact cause is unknown, it's believed that at least 10 percent of the general population has a hereditary predisposition to the disease, though it develops in only 2-3 percent of people.

Psoriasisanswers.com offers useful tools and educational information for people living with the disease.

  • The Psoriasis Answers Widget delivers new tips and helpful facts about psoriasis every week to a personal desktop and has an interactive symptom tracker. This tracker allows patients or caregivers to privately compile detailed information about ongoing symptoms. When preparing for a visit with a dermatologist, tracker information can be printed and shared to enhance patient and doctor conversations.
  • The Psoriasis Answers Kit, which can be ordered on Psoriasisanswers.com, includes an offline version of the symptom tracker in the form of a notepad with stickers, plus Q&A Cards with tips, interesting facts and practical advice for people with the condition.

Beyond symptom tracking, Psoriasisanswers.com offers a guide to jumpstart disease discussions during office visits to ensure patients make the most of their face time with their dermatologist.

"I greatly support these types of online resources being available to psoriasis patients," says Dr. Bruce Strober, assistant professor in the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "It's very important to have information about the type and frequency of symptoms that is as accurate as possible. These tools help patients prepare for their appointments so they might have more productive and informative conversations with their physician."

Felicia Williams, who has psoriasis and is featured on Psoriasisanswers.com, urges people to be proactive about managing their condition. "It's important to take advantage of all the great resources out there like the tools on Psoriasisanswers.com. I'm thrilled to be able to share my story with others and encourage them to take control of their disease."

Psoriasis Awareness Month is sponsored by major patient advocacy organizations to encourage broader public awareness of the condition and support for people with it.

About Psoriasis
Psoriasis is a chronic, immune disease that appears on the skin. It affects an estimated 125 million people worldwide. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick, scaly areas of skin. The most common form, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which are often itchy and painful and can crack and bleed. Currently, there is no cure but treatment can help control the condition. Treatment may include topical agents, phototherapy or systemic medications taken orally or by injection or infusion. More information can be found at Psoriasisanswers.com.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]